

# SATISFY: A EuroBloodNet Multicenter, Single-Arm Phase 2 Trial of Mitapivat in Adult Patients with Erythrocyte Membranopathies and Congenital Dyserythropoietic Anemia Type II – Results from the 8-Week Dose-Escalation Period

Thomas Doeven, MD<sup>1</sup>, Andreas Glenthøj, MD, PhD<sup>2</sup>, Richard van Wijk, PhD<sup>3</sup>, Evelyn Groot, PhD<sup>1</sup>, Joline L. Saes, MD, PhD<sup>1</sup>, Jennifer Bos<sup>3</sup>, Jonathan R.A. de Wilde, MD<sup>3</sup>, Minke A.E. Rab, MD, PhD<sup>3</sup>, Selma K Bendtsen, MSc<sup>2</sup>, Jesper Petersen, PhD<sup>2</sup>, Niels G Vejlstrup, MD, PhD<sup>4</sup>, Jens Helby, MD, PhD<sup>2</sup>, Adeline Gladieux, MSc<sup>5</sup>, Fatiha Chermat<sup>5</sup>, Pierre Fenaux, MD, PhD<sup>5</sup>, Kevin H.M. Kuo, MD, PhD<sup>6</sup>, Eduard J. van Beers, MD, PhD<sup>1</sup>

<sup>1</sup> Center for Benign Hematology, Thrombosis and Hemostasis - Van Creveldkliniek, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands

<sup>2</sup> Danish Red Blood Cell Center, Department of Hematology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

<sup>3</sup> Central Diagnostic Laboratory and Research, University Medical Center Utrecht, Utrecht University Utrecht, The Netherlands.

<sup>4</sup> Department of Cardiology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark

<sup>5</sup> EuroBloodNet, Paris, France

<sup>6</sup> Division of Hematology, University of Toronto, Toronto, Canada

**Background:** Erythrocyte membranopathies represent a heterogeneous group of diseases characterized by hemolysis resulting from structural and functional defects in cytoskeletal, (trans)membrane and ion-channel proteins. Congenital dyserythropoietic anemia type II (CDA II) is another form of rare hereditary anemia characterized by ineffective erythropoiesis and hemolysis. Current treatment options are mainly supportive. Mitapivat is a first-in-class oral allosteric activator of the pyruvate kinase (PK), a key glycolytic enzyme. Mitapivat enhances glycolysis, subsequently increasing ATP and decreasing 2,3-diphosphoglycerate within the red blood cell. Recent evidence suggests a relatively decreased PK activity in hereditary spherocytosis (HS), attributed to loss of membrane-bound PK due to impaired structural integrity.

**Methods:** This study (NCT05935202) aims to evaluate the safety and efficacy of mitapivat in patients with erythrocyte membranopathies and CDA II. This study is being conducted in the Netherlands and Denmark. Eligible subjects were adults with a genetically supported (ACMG class 3-5), non-transfusion dependent erythrocyte membranopathy or CDA II, with an average hemoglobin (Hb) concentration of <11.0 g/dL for females and <13.0 g/dL for males. Key exclusion criteria were known history of PK deficiency, regularly scheduled blood transfusion episodes, and/or any significant medical condition.

Here, we report data from all patients who completed the 8-week dose-escalation period, during which subjects initially received 50 mg of mitapivat twice daily (BID) for 4 weeks, followed by 100 mg BID. The primary endpoint was safety, as assessed by the occurrence of treatment-emergent adverse events (TEAEs). Secondary endpoints included efficacy, defined as a Hb response of  $\geq 1$  g/dL compared to baseline, as well as changes in hemolytic and erythropoietic markers.

*Results:* As of July 2024, the study has enrolled 24 patients. Of these, 18 patients (12 HS, 4 CDA II and 2 dehydrated hereditary stomatocytosis) completed the dose-escalation period, with a median age of 45 (range 24-79) years and 8/18 (44%) patients being female. Safety analyses revealed mostly (49/50) mild (grade 1-2) TEAEs, with headache and insomnia being the most frequently reported. One serious adverse event (grade 3) occurred, which was unrelated to treatment. Efficacy analyses showed a mean increase in Hb concentration of 1.0 g/dL (standard deviation  $\pm$  0.7 g/dL,  $p < 0.001$ ), with 11/18 (61%) patients reaching the efficacy endpoint of  $\geq 1$  g/dL increase (10 HS and 1 CDA II). Analyses of erythropoietic and hemolytic markers showed a significant mean decrease in reticulocytes and total bilirubin, with no significant change in LDH.

*Conclusion:* In the dose-escalation period of this phase 2 trial, mitapivat has shown initial improvements in hemoglobin and hemolytic markers, with a safety profile consistent with that observed in previous clinical trials.

*Key words:* Clinical trial, red blood cell, pyruvate kinase, mitapivat, erythrocyte membranopathies, hereditary spherocytosis, dehydrated hereditary stomatocytosis, congenital dyserythropoietic anemia type II

*Disclosures:* This study was funded by Agios Pharmaceuticals, Inc. **Andreas Glenthøj** has received consultancy fees and is an advisory board member for Agios, bluebird bio, Bristol Myers Squibb, Novartis, Novo Nordisk, and Pharmacosmos, and has received research support from Agios, Novo Nordisk, Saniona, and Sanofi. The remaining authors declare no competing financial interests. **Richard van Wijk** is consultant for Agios Pharmaceuticals, RR Mechatronics and Pfizer and has received research funding from Agios Pharmaceuticals, and Pfizer. **Jonathan R.A. de Wilde** has received research funding from Agios Pharmaceuticals. **Minke A.E. Rab** has received research funding from Pfizer, RR Mechatronics and Agios Pharmaceuticals. **Kevin H. M. Kuo** has received consultancy fees from Agios, Alexion, Bristol Myers Squibb, Forma Therapeutics, Novo Nordisk, Pfizer, Vertex Pharmaceuticals, membership of an entity's Board of Directors or advisory committees for Agios and Bioverativ/Sanofi/Sangamo, and research funding from Agios and Pfizer. **Jens Helby** has received research support from Sanofi. **Pierre Fenaux** has received research funding from BMS, Abbvie, Jazz Pharmaceuticals, Novartis, and Janssen; and had a consultancy with and received honoraria from BMS, Abbvie, Jazz Pharmaceuticals, and Novartis. **Eduard J. van Beers** is consultant for Agios Pharmaceuticals, and has received research funding from Agios Pharmaceuticals.

**Table 1: Safety analysis: incidence of treatment-emergent adverse events**


	<b>Grade 1</b>	<b>Grade 2</b>	<b>Grade 3</b>
<b>Total</b>	<b>N = 32</b>	<b>n=15</b>	<b>n=1</b>
<b>Abdominal pain</b>	1 (6%)	1 (6%)	
<b>Arthritis</b>	1 (6%)		
<b>Diarrhea</b>	1 (6%)		
<b>Dry eye</b>		1 (6%)	
<b>Dry mouth</b>	1 (6%)		
<b>Edema limbs</b>	1 (6%)		
<b>Fatigue</b>	3 (17%)		
<b>Flu like symptoms</b>	1 (6%)		
<b>Headache</b>	8 (44%)	1 (6%)	
<b>Hordeolum</b>	1 (6%)		
<b>Hot flashes</b>	1 (6%)		
<b>Hyperhidrosis</b>	1 (6%)		
<b>Infective arthritis</b>	1 (6%)		
<b>Insomnia</b>	6 (33%)	1 (6%)	
<b>Irritability</b>	1 (6%)		
<b>Libido decreased</b>	1 (6%)		
<b>Mucosal infection</b>		1 (6%)	
<b>Nausea</b>		1 (6%)	
<b>Neck pain</b>		1 (6%)	
<b>Non-cardiac chest pain</b>	1 (6%)	1 (6%)	
<b>Pain in extremity</b>	1 (6%)		
<b>Palpitations</b>	1 (6%)		
<b>Phlebitis</b>		1 (6%)	
<b>Skin infection</b>			1 (6%) <sup>1</sup>
<b>Upper respiratory infection</b>		5 (28%)	
<b>Urinary tract infection</b>		1 (6%)	

Occurrence of treatment-emergent adverse events during the dose-escalation period for all patients who have completed the dose-escalation period as of July 2024. Adverse events were graded using the Common Terminology Criteria for Adverse Events.

Total number of adverse events are presented for each grade. Data is presented as n (%), with the percentage representing the incidence of adverse events within the study cohort (n=18). Adverse events occurring multiple times within the same category in the same participant are only included once in this table.

<sup>1</sup>Grade 3 AE was a SAE, not related to the study drug, in a patient admitted to the hospital with erysipelas of the right extremity.

**Figure 1:** Efficacy analysis: changes in hemoglobin and in hemolytic and erythropoietic markers



Means are presented for the study population that completed the 8-week dose escalation period as of July 2024 (n = 18). Error bars represent the standard deviation. Dashed line in figure A represents the primary efficacy endpoint of  $\geq 1.0$  g/dL increase in hemoglobin concentration compared to baseline. (A) Mean change in hemoglobin concentration compared to baseline (B) Mean hemoglobin concentration (C) Mean absolute reticulocyte count (D) Mean bilirubin concentration (E) Mean LDH concentration. Abbreviations: SD: Standard deviation, LDH: Lactate dehydrogenase

**Table 2:** Efficacy analysis: changes in hemoglobin and in hemolytic and erythropoietic markers

	Baseline (n = 18) <sup>1</sup>	Week 8 (n = 18) <sup>1</sup>	Mean difference <sup>2</sup>	P-value <sup>3</sup>
<b>Hemoglobin (g/dL)</b>	10.4 (1.6)	11.4 (2.0)	1.0 (0.7 to 1.3)	<0.001
<b>Reticulocytes (x 10<sup>9</sup>/L)</b>	248 (177)	183 (121)	-64.8 (-96.8 to -32.8)	<0.001
<b>Bilirubin (mg/dL)</b>	3.3 (2.0)	1.9 (0.8)	-1.3 (-2.1 to -0.5)	0.003
<b>LDH (U/L)</b>	216 (64)	223 (69)	6.3 (-7.3 to 20.0)	0.342

Mean values and mean differences from baseline compared to the end of the dose-escalation period are presented for all patients that have completed the dose-escalation period as of July 2024.

<sup>1</sup> Mean (SD) <sup>2</sup> Mean difference (95% CI) <sup>3</sup> P-values calculated using paired sample t test

Abbreviations: SD: Standard deviation, LDH: Lactate dehydrogenase, CI: Confidence interval